Terms amended in Bellus' acquisition of Thallion

23 July 2013

Canada-based drugmaker Bellus Health (TSX: BLU) has amended its agreement to acquire fellow Canadian company Thallion Pharmaceuticals (TSX: TLN) to appease Thallion’s largest shareholder.

The original acquisition was for around C$6.33 million ($6.02 million) in cash or C$0.1765 per share (on a fully-diluted basis) with the issue of contingent value rights (CVRs) to entitle the holders to additional payments of up to about C$7.66 million, or C$0.2135 per CVR, if product revenue milestones are achieved. But Jaguar Financial, Thallion’s largest single shareholder (10.1%), indicated it would vote against the deal unless CVR terms were significantly raised ( The Pharma Letter July 1).

Terms amended to remove C$10 million threshold

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology